AbbVie Drops 1.42% in Trading Volume Ranking 82nd Amid Oncology Breakthroughs and Strategic Alliance

Volume AlertsWednesday, May 28, 2025 8:00 pm ET
1min read
ABBV0.00%

AbbVie Inc. (ABBV) closed at $150.23, down 1.42% on May 28, 2025, with a trading volume of $879 million, ranking 82nd in the day's stock market activity.

AbbVie has made significant strides in its oncology pipeline, presenting new data across a range of difficult-to-treat solid tumors and blood cancers. The company's novel investigational antibody-drug conjugates, including telisotuzumab adizutecan, are part of this progress, showcasing the breadth and depth of its oncology portfolio.

In addition to its advancements in oncology, AbbVie has formed a strategic alliance with Sarah Cannon Research Institute (SCRI). This collaboration aims to accelerate the development of innovative cancer therapies through enhanced scientific engagement and operational synergies. SCRI's extensive research network, comprising over 1,300 physicians and more than 200 locations across the U.S., will play a crucial role in this partnership. The alliance leverages SCRI's advanced research operational capabilities, including its Accelero model, to maximize site contributions and optimize clinical trial delivery.

Comments



Add a public comment...
No comments

No comments yet

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.